Novo Nordisk A/S $NVO Shares Bought by WealthTrust Axiom LLC

WealthTrust Axiom LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 105.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,595 shares of the company’s stock after buying an additional 9,526 shares during the quarter. WealthTrust Axiom LLC’s holdings in Novo Nordisk A/S were worth $1,283,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVO. First Hawaiian Bank lifted its holdings in Novo Nordisk A/S by 0.6% in the first quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock valued at $1,556,000 after acquiring an additional 142 shares during the period. Anchor Investment Management LLC lifted its stake in shares of Novo Nordisk A/S by 1.1% in the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock valued at $944,000 after purchasing an additional 150 shares during the period. Foster Dykema Cabot & Partners LLC boosted its holdings in Novo Nordisk A/S by 3.8% during the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock worth $319,000 after buying an additional 166 shares in the last quarter. Werba Rubin Papier Wealth Management grew its position in Novo Nordisk A/S by 4.1% during the second quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock worth $302,000 after buying an additional 173 shares during the period. Finally, Atwood & Palmer Inc. increased its holdings in Novo Nordisk A/S by 31.8% in the second quarter. Atwood & Palmer Inc. now owns 737 shares of the company’s stock valued at $51,000 after buying an additional 178 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $48.75 on Friday. The company has a market cap of $217.67 billion, a P/E ratio of 13.39, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $112.52. The business has a fifty day simple moving average of $53.05 and a 200-day simple moving average of $59.86.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on NVO. Morgan Stanley lowered Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and lowered their target price for the company from $59.00 to $47.00 in a report on Monday, September 29th. Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Finally, TD Cowen lowered their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $57.40.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.